Please Wait
Applying Filters...
menu
    • menu
    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Synnat Pharma is one of the leading active pharmaceutical ingredients and intermediates manufacturers.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Peginterferon Alfa 2A

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Eiger obtains DSMB approval to progress Phase III Covid-19 therapy trial
    Eiger obtains DSMB approval to progress Phase III Covid-19 therapy trial

    21 Sep 2021

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/eiger-dsmb-progress-trial/

    CLINICALTRIALSARENA
    21 Sep 2021
    Share Share
    Hoffmann-La Roche`s Pegasys (peginterferon) Receives Supplemental Approval in US
    Hoffmann-La Roche`s Pegasys (peginterferon) Receives Supplemental Approval in US

    20 Oct 2020

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103964

    FDA
    20 Oct 2020
    Share Share
    Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda
    Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda

    20 Aug 2019

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/eiger-announces-fda-breakthrough-therapy-designation-for-peginterferon-lambda-for-treatment-of-hepatitis-delta-virus-infection-300903974.html

    PR NEWSWIRE
    20 Aug 2019
    Share Share
    Ascletis opens Clinical Development Shanghai Center
    Ascletis opens Clinical Development Shanghai Center

    12 Aug 2019

    // BIOSPECTRUMASIA

    https://www.biospectrumasia.com/news/28/14205/ascletis-opens-clinical-development-shanghai-center.html

    BIOSPECTRUMASIA
    12 Aug 2019
    Share Share